German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP )
Photodermatology, Photoimmunology & Photomedicine · 2025
DOI: 10.1111/phpp.13012 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Photodermatology, Photoimmunology & Photomedicine, 2025. Verfasst von Bernhard Homey und 12 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Dermatology, Medical Faculty, Porphyria Specialist Center, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Protoporphyria, Erythropoietic, alpha-MSH, Registries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CLINUVEL (UK) LTD.
Abstract (Originalsprache)
Background
Afamelanotide 16 mg (SCENESSE) is the first approved treatment for erythropoietic protoporphyria (EPP). EPP is a rare autosomal recessive inherited disorder of the haem biosynthesis pathway, where patients experience severe and debilitating acute phototoxicity. It affects at least one in 140,000 of the European population. A postauthorisation safety study (PASS) and a disease registry were imposed as conditions of the European marketing authorisation.
Objectives
Evaluate the short‐ and long‐term safety and clinical effectiveness of afamelanotide 16 mg in EPP patients enrolled in the PASS in Germany.
Methods
The PASS (EUPAS13004) is an ongoing observational study collecting safety and effectiveness variables from treated and untreated EPP patients in the European EPP Disease Registry. Patients ( n = 200, none untreated) received afamelanotide according to the summary of product characteristics. Treatment‐emergent adverse events were collected as safety variables. Clinical effectiveness was assessed with the EPP‐QoL tool and through treatment continuity.
Results
The short‐ and long‐term safety and benefit–risk profile of afamelanotide under real‐world conditions is consistent with the positive safety profile seen in clinical trials. EPP patients reported a significant increase in QoL compared with baseline values ( p < 0.0001) and 91.0% of patients who started treatment continue being treated. The safety profile of afamelanotide in patients over 70 years of age is consistent with the overall patient population.
Conclusions
Afamelanotide treatment was highly effective and associated with a higher QoL in EPP patients. The study shows a positive safety profile of afamelanotide, with the treatment providing an ongoing clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dept. of Dermatology, Medical Faculty, Porphyria Specialist Center, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
- Institute for Allergology, Charite, Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin und Humboldt Universität zu Berlin, Berlin, Germany; FrauenhoferInstitute for Translational Medicine and Phar…
- Clinic for Internal Medicine II, Porphyria Specialist Center, Chemnitz, Germany.
- University Medical Center of Johannes Gutenberg University, Mainz, Germany.
- Clinuvel (UK) Ltd, Leatherhead, UK.
Förderung
- CLINUVEL (UK) LTD
Zitieren
APA
Homey, B., Schelonke, K., Schlegel, C. M., Bruch-Gerharz, D., Weller, K., Kiefer, L., Stölzel, U., Staubach-Renz, P., Wegner, J., Keller-Melchior, R., Walker, G., Bochno, M., & Bilbao, P. (2025). German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP ). Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.13012
Vancouver
Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, et al. German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP ). Photodermatology, Photoimmunology & Photomedicine. 2025. doi:10.1111/phpp.13012
BibTeX
@article{Homey2025,
author = {Homey, Bernhard and Schelonke, Kathrin and Schlegel, Carla Marie and Bruch-Gerharz, Daniela and Weller, Karsten and Kiefer, Lea and Stölzel, Ulrich and Staubach-Renz, Petra and Wegner, Joanna and Keller-Melchior, Regine and Walker, Gillian and Bochno, Malgorzata and Bilbao, Pilar},
title = {German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP )},
journal = {Photodermatology, Photoimmunology & Photomedicine},
year = {2025},
doi = {10.1111/phpp.13012}
}
EUVIMED